China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
